Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage.
BACKGROUND
Intracerebral hemorrhage (ICH) constitutes 10% to 15% of all strokes. Despite several existing outcome prediction models for ICH, there are some factors with equivocal value as well as others that still have not been evaluated.


METHODS
All patients with first ever supratentorial ICH presenting to our institution between December 1995 and December 2002 were prospectively enrolled into the study. Patients with historic modified Rankin Scale > 2 and those under anticoagulant treatment or with multiple ICH were excluded. The following parameters were analyzed in 194 consecutive patients: age, gender, past history of hypertension, diabetes mellitus, hypercholesterolemia, past history of ischemic stroke, presence of ischemic heart disease or cardioembolic disease, current antiplatelet treatment, current alcohol overuse, smoking, Glasgow Coma Scale score (GSS) at admission, volume and location (deep or lobar) of ICH, ventricular extension, glycemia and temperature at admission, and leukoaraiosis. We correlated these data with the 30-day mortality identifying the independent predictors by logistic regression analysis.


RESULTS
Factors independently associated with 30-day mortality were: age, Glasgow Coma Scale score at admission, ICH volume, ventricular extension, glucose level at admission, and previous antiplatelet use.


CONCLUSIONS
Apart from the classical outcome predictors, the previous use of antiplatelet agents and the glucose value at admission are independent predictors of 30-day mortality in patients suffering a supratentorial ICH.
Roquer
Jaume
J
Unitat d'Ictus, Servei de Neurología, Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona, Spain. 35826@imas.imim.es
Rodríguez Campello
Ana
A
Gomis
Meritxell
M
Ois
Angel
A
Puente
Victor
V
Munteis
Elvira
E
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D015600:Glasgow Coma Scale; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012189:Retrospective Studies; D012720:Severity of Illness Index
D010975:Platelet Aggregation Inhibitors; D005947:Glucose
Neurology. 2000 Jun 27;54(12):2298-301
10881256
Stroke. 2000 Nov;31(11):2558-62
11062275
J Neurol. 2002 Dec;249(12):1704-9
12529793
Diabetes Care. 2000 Oct;23(10):1527-32
11023147
Stroke. 2001 Feb;32(2):438-41
11157179
Stroke. 2003 Apr;34(4):840-8
12649515
Cerebrovasc Dis. 2001;11(3):195-200
11306767
Stroke. 2003 Feb;34(2):387-91
12574547
Stroke. 1991 May;22(5):571-6
2028484
Acta Neurol Scand. 1997 Sep;96(3):174-82
9300072
J Neurol Sci. 1999 Jul 1;166(2):107-14
10475103
Stroke. 1998 May;29(5):887-94
9596230
Arch Neurol. 1995 Dec;52(12):1193-200
7492294
JAMA. 1998 Dec 9;280(22):1930-5
9851479
Stroke. 1997 Jun;28(6):1185-8
9183348
Stroke. 2003 Jul;34(7):1717-22
12805488
Stroke. 2003 May;34(5):1151-5
12663877
J Neurosurg. 2002 Sep;97(3):531-6
12296635
Crit Care Med. 1999 Mar;27(3):617-21
10199544
Cerebrovasc Dis. 1999 Jan-Feb;9(1):10-21
9873158
Stroke. 2001 Apr;32(4):891-7
11283388
Stroke. 1998 Jun;29(6):1160-6
9626289
Stroke. 2001 Feb;32(2):399-404
11157173
Stroke. 1988 Feb;19(2):192-5
3344534
Stroke. 1995 Oct;26(10 ):1764-7
7570722
Eur Neurol. 2000;43(4):209-14
10828650
J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):653-7
1527534
Neurol Res. 2000 Dec;22(8):791-6
11149240
Neurology. 2000 Oct 10;55(7):947-51
11061249
Stroke. 1991 Jan;22(1):1-6
1987664
Stroke. 1997 Jul;28(7):1396-400
9227690
Stroke. 1996 Aug;27(8):1304-5
8711791
Stroke. 1995 Dec;26(12 ):2249-53
7491645
Stroke. 1993 Jul;24(7):987-93
8322400